These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33556094)

  • 1. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study.
    Soeroto AY; Pratiwi C; Santoso P; Lestari BW
    PLoS One; 2021; 16(2):e0246284. PubMed ID: 33556094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA; Burhan E; Nawas A; Soepandi PZ; Sutoyo DK; Agustin H; Isbaniah F; Dowdy DW
    Int J Tuberc Lung Dis; 2014 May; 18(5):564-70. PubMed ID: 24903794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.
    Shibabaw A; Gelaw B; Wang SH; Tessema B
    PLoS One; 2018; 13(6):e0198080. PubMed ID: 29944658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
    Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia.
    Soeroto AY; Nurhayati RD; Purwiga A; Lestari BW; Pratiwi C; Santoso P; Kulsum ID; Suryadinata H; Ferdian F
    PLoS One; 2022; 17(1):e0263304. PubMed ID: 35089981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country.
    Ige OM; Oladokun RE
    Indian J Tuberc; 2018 Oct; 65(4):322-328. PubMed ID: 30522620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
    Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
    Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Survival Analysis of Successful and Poor Treatment Outcome Among Patients with Drug-Resistant Tuberculosis and the Associated Factors: A Retrospective Cohort Study.
    Machmud PB; Gayatri D; Ronoatmodjo S
    Acta Med Indones; 2021 Apr; 53(2):184-193. PubMed ID: 34251347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting sputum smear conversion and treatment outcomes in new smear-positive pulmonary tuberculosis.
    Unsematham S; Kateruttanakul P
    J Med Assoc Thai; 2013 Jun; 96(6):644-9. PubMed ID: 23951819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of previous tuberculosis treatment history on acid-fast bacilli smear and culture conversion.
    Lee J; Lee BJ; Yoon HI; Lee CT; Lee JH
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1344-8. PubMed ID: 23107634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment.
    Tierney DB; Franke MF; Becerra MC; Alcántara Virú FA; Bonilla CA; Sánchez E; Guerra D; Muñoz M; Llaro K; Palacios E; Mestanza L; Hurtado RM; Furin JJ; Shin S; Mitnick CD
    PLoS One; 2014; 9(9):e108035. PubMed ID: 25238411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
    Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Indarti HT; Kristin E; Soedarsono S; Endarti D
    Int J Mycobacteriol; 2022; 11(3):261-267. PubMed ID: 36260444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV; Gammino VM; Bayona J; Becerra MC; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon.
    Kuaban A; Balkissou AD; Ekongolo MCE; Nsounfon AW; Pefura-Yone EW; Kuaban C
    Pan Afr Med J; 2021; 38():229. PubMed ID: 34046134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
    Thai PVK; Ha DTM; Hanh NT; Day J; Dunstan S; Nhu NTQ; Kiet VS; Lan NH; Dung NH; Lan NTN; Thuong NT; Lan NN; Liễu PTT; Hồng NT; Điệp ĐC; Thanh NTK; Hội NV; Nghĩa NV; Đại TN; Minh HQ; Thơm NV; Farrar J; Caws M
    BMC Infect Dis; 2018 Mar; 18(1):112. PubMed ID: 29510687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis.
    Park SK; Lee CM; Heu JP; Song SD
    Int J Tuberc Lung Dis; 2002 Feb; 6(2):143-9. PubMed ID: 11931413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.
    Kurbatova EV; Cegielski JP; Lienhardt C; Akksilp R; Bayona J; Becerra MC; Caoili J; Contreras C; Dalton T; Danilovits M; Demikhova OV; Ershova J; Gammino VM; Gelmanova I; Heilig CM; Jou R; Kazennyy B; Keshavjee S; Kim HJ; Kliiman K; Kvasnovsky C; Leimane V; Mitnick CD; Quelapio I; Riekstina V; Smith SE; Tupasi T; van der Walt M; Vasilyeva IA; Via LE; Viiklepp P; Volchenkov G; Walker AT; Wolfgang M; Yagui M; Zignol M
    Lancet Respir Med; 2015 Mar; 3(3):201-9. PubMed ID: 25726085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.